Biomarkers and clinical outcomes after cessation of tezepelumab after 2 years of treatment (DESTINATION)Biomarkers and clinical outcomes after cessation of tezepelumab after 2 years of treatment (DESTINATION) - Milan 2023

Biological treatments for asthma: a new era in severe asthma management

Chair(s): Apostolos Bossios, Lena Uller

Session type: Oral presentation

Biomarkers and clinical outcomes after cessation of tezepelumab after 2 years of treatment (DESTINATION)Biomarkers and clinical outcomes after cessation of tezepelumab after 2 years of treatment (DESTINATION)

Christopher E. Brightling

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Phase I safety and tolerance study of the inhalable anti IL-4R? single domain antibody, LQ036, demonstrates promising clinical profile to treat asthma

Yakun Wan

Replay

Abstract

Slides

Bronchial submucosal eosinophils predict clinical remission better than blood eosinophils and FeNO in severe uncontrolled asthma treated with biological therapy

Hanaa Shafiek

Replay

Poster

Abstract

Slides

Non-T2 cytokines post Benralizumab associate with residual symptoms

Manali Mukherjee

Replay

Abstract

Slides

Christopher E. Brightling

Replay

Poster

Abstract

Slides

Long-Term Dupilumab Efficacy in Patients with Type 2 Asthma by Age of Onset: LIBERTY ASTHMA TRAVERSE

William Busse

Replay

Poster

Abstract

Slides

Tezepelumab can restore normal lung function in patients with severe, uncontrolled asthma

Ian Douglas Pavord

Replay

Poster

Abstract

Slides

The proportion of patients achieving low biomarker levels with tezepelumab treatment in the phase 3 NAVIGATOR study

David J Jackson

Replay

Poster

Abstract

Slides

Changes in serum total IgE after cessation of tezepelumab after 2 years of treatment (DESTINATION)

Marco Caminati

Replay

Poster

Abstract

Slides

Durability of Benralizumab-induced remission in severe asthma: an analysis of the BORA study

Marek Lommatzsch

Replay

Poster

Abstract

Slides

Parasitic Infections and Biological Therapies Targeting Type 2 Inflammation: a Vigibase® Study.

Laurent Guilleminault

Replay

Abstract

Slides

Discussion and Q&A

Replay

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}